Advertisement
Advertisement
ELUT
Elutia Inc. Class A Common Stock
1.12
USDSponsored
+0.05
+4.72%
Mar 25, 15:59 UTC -4
Closed
Pre-Market
1.10
-0.02
-1.34%
ELUT Earnings Reports
Positive Surprise Ratio
ELUT beat 8 of 22 last estimates.
36%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$3.06M
/-$0.15
Implied change from Q4 25 (Revenue/ EPS)
-6.45%
/-110.14%
Implied change from Q1 25 (Revenue/ EPS)
-49.25%
/+50.00%
Elutia Inc. Class A Common Stock earnings per share and revenue
On Mar 11, 2026, ELUT reported earnings of 1.48 USD per share (EPS) for Q4 25, beating the estimate of -0.14 USD, resulting in a 1136.41% surprise. Revenue reached 3.27 million, compared to an expected 3.37 million, with a -2.82% difference. The market reacted with a +27.19% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.15 USD, with revenue projected to reach 3.06 million USD, implying an decrease of -110.14% EPS, and decrease of -6.45% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were Elutia Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Elutia Inc. Class A Common Stock reported EPS of $1.48, beating estimates by 1136.41%, and revenue of $3.27M, -2.82% below expectations.
How did the market react to Elutia Inc. Class A Common Stock's Q4 2025 earnings?
The stock price moved up 27.19%, changed from $0.69 before the earnings release to $0.88 the day after.
When is Elutia Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Elutia Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, Elutia Inc. Class A Common Stock is expected to report EPS of -$0.15 and revenue of $3.06M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement